Rivfloza (nedosiran) prior authorization for PH1
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
Defines UnitedHealthcare prior authorization and medical necessity requirements for Rivfloza (nedosiran) for treatment of primary hyperoxaluria type 1 (PH1) in patients aged 2 years and older with relatively preserved kidney function; applies to providers submitting for coverage under UHC medical benefit.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.